What is Lifesci Capital’s Forecast for AURA FY2024 Earnings?

Aura Biosciences, Inc. (NASDAQ:AURA) – Equities researchers at Lifesci Capital issued their FY2024 EPS estimates for Aura Biosciences in a research note issued on Tuesday, January 21st. Lifesci Capital analyst O. Mccammon forecasts that the company will earn ($1.65) per share for the year. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.67) per share. Lifesci Capital also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.42) EPS and FY2025 earnings at ($2.52) EPS.

A number of other equities research analysts also recently issued reports on the company. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a report on Thursday, November 14th. BTIG Research upped their price objective on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Finally, Scotiabank boosted their price target on Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Trading Up 2.1 %

Shares of AURA stock opened at $8.10 on Friday. The stock has a market capitalization of $404.60 million, a P/E ratio of -4.68 and a beta of 0.30. The firm’s 50 day moving average is $8.45 and its 200 day moving average is $8.91. Aura Biosciences has a 12-month low of $6.63 and a 12-month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02.

Insider Activity

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Janet Jill Hopkins sold 11,822 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the sale, the insider now directly owns 151,693 shares in the company, valued at $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,531 shares of company stock worth $345,454 over the last quarter. Insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of AURA. China Universal Asset Management Co. Ltd. bought a new position in shares of Aura Biosciences in the fourth quarter worth about $87,000. JPMorgan Chase & Co. boosted its holdings in shares of Aura Biosciences by 107.5% in the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock valued at $477,000 after purchasing an additional 27,718 shares during the period. Franklin Resources Inc. grew its stake in Aura Biosciences by 14.8% in the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock worth $15,571,000 after purchasing an additional 215,597 shares in the last quarter. Barclays PLC increased its holdings in Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares during the period. Finally, Geode Capital Management LLC raised its position in Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock valued at $8,990,000 after purchasing an additional 39,379 shares in the last quarter. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.